Armodafinil — Membership Pricing

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Sleep Apnea

• Modafinil

Other medications in Sleep Disorders

• Doxepin
• Eszopiclone
• Melatonin
• Zolpidem

About Armodafinil

Armodafinil is a medication prescribed to improve wakefulness in individuals struggling with excessive sleepiness due to certain sleep disorders. If you're looking for an effective way to manage your condition and save significantly on your prescription, TheDrugClub offers an incredible opportunity to get armodafinil at an unbeatable price, often $0, with convenient free home delivery.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Armodafinil is approved for (FDA label)

NUVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Limitations of Use In OSA, NUVIGIL is indicated to treat excessive sleepiness and not as treatment for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL for excessive sleepiness.

Source: Read the full FDA label on DailyMed. Label effective date: September 2, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Armodafinil (FDA label)

50 mg – round, white to off-white tablet with on one side and "205" on the other 150 mg – oval, white to off-white tablet with on one side and "215" on the other 200 mg – rounded, rectangular, white to off-white tablet with on one side and "220" on the other 250 mg – oval, white to off-white tablet with on one side and "225" on the other Tablets: 50 mg, 150 mg, 200 mg, and 250 mg. ( 3 ) stylized c stylized c stylized c stylized c

Source: FDA prescribing information (DailyMed). Set ID: 3dd49302-f757-d945-e063-6294a90afcba. SPL document ID: 3dd48c06-8784-6926-e063-6294a90a7590. Label effective date: September 2, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Armodafinil (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Serious Dermatologic Reactions [see Warnings and Precautions ( 5.1 )] Drug Reaction with Eosinophilia and System Symptoms (DRESS)/Multiorgan Hypersensitivity [see Warnings and Precautions ( 5.2 )] Angioedema and Anaphylaxis Reactions [see Warnings and Precautions ( 5.3 )] Persistent Sleepiness [see Warnings and Precautions ( 5.4 )] Psychiatric Symptoms [see Warnings and Precautions ( 5.5 )] Effects on Ability to Drive and Use Machinery [see Warnings and Precautions ( 5.6 )] Cardiovascular Events [see Warnings and Precautions ( 5.7 )] Most common adverse reactions (≥5%): headache, nausea, dizziness, and insomnia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 3dd49302-f757-d945-e063-6294a90afcba. SPL document ID: 3dd48c06-8784-6926-e063-6294a90a7590. Label effective date: September 2, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Armodafinil (FDA label)

NUVIGIL is contraindicated in patients with known hypersensitivity to modafinil or armodafinil or its inactive ingredients [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 )] . NUVIGIL is contraindicated in patients with known hypersensitivity to modafinil or armodafinil. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 3dd49302-f757-d945-e063-6294a90afcba. SPL document ID: 3dd48c06-8784-6926-e063-6294a90a7590. Label effective date: September 2, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Armodafinil (FDA label)

Serious Rash, including Stevens-Johnson Syndrome: discontinue NUVIGIL at the first sign of rash, unless the rash is clearly not drug-related. ( 5.1 ) DRESS/Multi-organ Hypersensitivity Reactions: if suspected, discontinue NUVIGIL. ( 5.2 ) Angioedema and Anaphylaxis Reactions: if suspected, discontinue NUVIGIL. ( 5.3 ) Persistent Sleepiness: assess patients frequently for degree of sleepiness and, if appropriate, advise patients to avoid driving or engaging in any other potentially dangerous activity. ( 5.4 ) Psychiatric Symptoms: use particular caution in treating patients with a history of psychosis, depression, or mania. Consider discontinuing NUVIGIL if psychiatric symptoms develop. ( 5.5 ) Known Cardiovascular Disease: consider increased monitoring. ( 5.7 ) 5.1 Serious Dermatologic Reactions, including Stevens-Johnson Syndrome and Toxic Epidermal Necrosis Serious rash requiring hospitalization and discontinuation of treatment has been reported in association with the use of NUVIGIL (armodafinil) or modafinil (the racemic mixture of S- and R-enantiomers).

Source: FDA prescribing information (DailyMed). Set ID: 3dd49302-f757-d945-e063-6294a90afcba. SPL document ID: 3dd48c06-8784-6926-e063-6294a90a7590. Label effective date: September 2, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Armodafinil (FDA label)

Effects of NUVIGIL on CYP3A4/5 Substrates The clearance of drugs that are substrates for CYP3A4/5 (e.g., steroidal contraceptives, cyclosporine, midazolam, and triazolam) may be increased by NUVIGIL via induction of metabolic enzymes, which results in lower systemic exposure. Dosage adjustment of these drugs should be considered when these drugs are used concomitantly with NUVIGIL [see Clinical Pharmacology (12.3)] . The effectiveness of steroidal contraceptives may be reduced when used with NUVIGIL and for one month after discontinuation of therapy. Alternative or concomitant methods of contraception are recommended for patients taking steroidal contraceptives (e.g., ethinyl estradiol) when treated concomitantly with NUVIGIL and for one month after discontinuation of NUVIGIL treatment.

Source: FDA prescribing information (DailyMed). Set ID: 3dd49302-f757-d945-e063-6294a90afcba. SPL document ID: 3dd48c06-8784-6926-e063-6294a90a7590. Label effective date: September 2, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.